Background <p>The orally available toll-like receptor 7 (TLR7) agonist prodrug RO7119929 is converted to active drug predominantly in the liver, where it is hypothesized to reprogram the local immune microenvironment. We aimed to explore the safety, pharmacokinetics (PK), and preliminary antitumor activity and obtain the proof-of-mechanism for RO7119929 in patients with liver cancer.</p> Methods <p>RO7119929 was investigated in mouse tumors…
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers
Journal for ImmunoTherapy of Cancer | | Yoo, C., Fabregat-Franco, C., Lin, C.-C., Qvortrup, C., Oh, D.-Y., Yau, T., Kim, H.-D., Castet, F., Ponz Sarvise, M., Hsu, C., Rohrberg, K. S., Lichtenegger, F. S., Franjkovic, I., Kratochwil, N. A., Bessa, J., Rossmann, E., Schwalie, P. C., Rieder, N., Pöschinger, T., Sie, C. G., Dettling, S., Schlenker, R., Jiang, T., Dai, C., Yun, H., Hall, E., Yeo Te-Ying, A., Hoves, S., Cannarile, M. A., Schiff, C., Sangro, B.
Topics: blood-cancer, liver-cancer, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer